TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner
Само за регистроване кориснике
2015
Аутори
Kotur, NikolaDokmanović, Lidija
Janić, Dragana
Stanković, Biljana
Krstovski, Nada
Tošić, Nataša
Katsila, Theodora
Patrinos, George P.
Zukić, Branka
Pavlović, Sonja
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Aims: 6-mercaptopurine influences in vitro TPMT gene expression in a TPMT promoter variable number of tandem repeats (VNTR)-dependent manner. We studied TPMT expression following 6-mercaptopurine and methotrexate administration in childhood acute lymphoblastic leukemia (ALL) patients and the pharmacogenomic potential of the VNTR architecture. Materials & methods:TPMT gene expression was determined in childhood ALL patients at diagnosis (n = 57) and during the maintenance therapy (n = 27). Results: A threefold increase of TPMT gene expression was obtained during maintenance therapy, modulated by the architecture of the VNTR region. Conclusion: The TPMT promoter genetic variants need to be considered at the very beginning of the maintenance therapy for childhood ALL patients. The TPMT promoter VNTR region may serve as a pharmacogenomic biomarker when introducing thiopurine therapy.
Кључне речи:
VNTR / variable number of tandem repeats / TPMT genetic variations / TPMT expression / pharmacogenomics / maintenance therapy / childhood acute lymphoblastic leukemia / 6-mercaptopurineИзвор:
Pharmacogenomics, 2015, 16, 15, 1701-1712Издавач:
- Future Medicine Ltd, London
Финансирање / пројекти:
- Ретке болести: молекуларна патофизиологија, дијагностички и терапијски модалитети и социјални, етички и правни аспекти (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-41004)
DOI: 10.2217/pgs.15.109
ISSN: 1462-2416
PubMed: 26411491
WoS: 000363398100003
Scopus: 2-s2.0-84949292673
Институција/група
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Kotur, Nikola AU - Dokmanović, Lidija AU - Janić, Dragana AU - Stanković, Biljana AU - Krstovski, Nada AU - Tošić, Nataša AU - Katsila, Theodora AU - Patrinos, George P. AU - Zukić, Branka AU - Pavlović, Sonja PY - 2015 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/842 AB - Aims: 6-mercaptopurine influences in vitro TPMT gene expression in a TPMT promoter variable number of tandem repeats (VNTR)-dependent manner. We studied TPMT expression following 6-mercaptopurine and methotrexate administration in childhood acute lymphoblastic leukemia (ALL) patients and the pharmacogenomic potential of the VNTR architecture. Materials & methods:TPMT gene expression was determined in childhood ALL patients at diagnosis (n = 57) and during the maintenance therapy (n = 27). Results: A threefold increase of TPMT gene expression was obtained during maintenance therapy, modulated by the architecture of the VNTR region. Conclusion: The TPMT promoter genetic variants need to be considered at the very beginning of the maintenance therapy for childhood ALL patients. The TPMT promoter VNTR region may serve as a pharmacogenomic biomarker when introducing thiopurine therapy. PB - Future Medicine Ltd, London T2 - Pharmacogenomics T1 - TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner EP - 1712 IS - 15 SP - 1701 VL - 16 DO - 10.2217/pgs.15.109 ER -
@article{ author = "Kotur, Nikola and Dokmanović, Lidija and Janić, Dragana and Stanković, Biljana and Krstovski, Nada and Tošić, Nataša and Katsila, Theodora and Patrinos, George P. and Zukić, Branka and Pavlović, Sonja", year = "2015", abstract = "Aims: 6-mercaptopurine influences in vitro TPMT gene expression in a TPMT promoter variable number of tandem repeats (VNTR)-dependent manner. We studied TPMT expression following 6-mercaptopurine and methotrexate administration in childhood acute lymphoblastic leukemia (ALL) patients and the pharmacogenomic potential of the VNTR architecture. Materials & methods:TPMT gene expression was determined in childhood ALL patients at diagnosis (n = 57) and during the maintenance therapy (n = 27). Results: A threefold increase of TPMT gene expression was obtained during maintenance therapy, modulated by the architecture of the VNTR region. Conclusion: The TPMT promoter genetic variants need to be considered at the very beginning of the maintenance therapy for childhood ALL patients. The TPMT promoter VNTR region may serve as a pharmacogenomic biomarker when introducing thiopurine therapy.", publisher = "Future Medicine Ltd, London", journal = "Pharmacogenomics", title = "TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner", pages = "1712-1701", number = "15", volume = "16", doi = "10.2217/pgs.15.109" }
Kotur, N., Dokmanović, L., Janić, D., Stanković, B., Krstovski, N., Tošić, N., Katsila, T., Patrinos, G. P., Zukić, B.,& Pavlović, S.. (2015). TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner. in Pharmacogenomics Future Medicine Ltd, London., 16(15), 1701-1712. https://doi.org/10.2217/pgs.15.109
Kotur N, Dokmanović L, Janić D, Stanković B, Krstovski N, Tošić N, Katsila T, Patrinos GP, Zukić B, Pavlović S. TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner. in Pharmacogenomics. 2015;16(15):1701-1712. doi:10.2217/pgs.15.109 .
Kotur, Nikola, Dokmanović, Lidija, Janić, Dragana, Stanković, Biljana, Krstovski, Nada, Tošić, Nataša, Katsila, Theodora, Patrinos, George P., Zukić, Branka, Pavlović, Sonja, "TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner" in Pharmacogenomics, 16, no. 15 (2015):1701-1712, https://doi.org/10.2217/pgs.15.109 . .